News

Featured News

View ASX Announcements here.

Investor Webinar - Starpharma and Medicxi Partnership: Petalion Therapeutics (9 April 2024)

Apr 10th, 2024

Starpharma hosted an investor webinar on Tuesday, 9 April 2024. The session focused on the ASX Announcement lodged on 8 April 2024, 'Starpharma and Medicxi Partnership Petalion Therapeutics', about the strategic partnership with Medicxi and the formation of a new company called Petalion Therapeutics.

Investor Webinar Notification – Starpharma x Medicxi Partnership (ASX Announcement)

Apr 8th, 2024

Starpharma (ASX: SPL, OTCQX: SPHRY) is pleased to announce that it will host an investor webinar on Tuesday, 9 April 2024.

Medicxi and Starpharma create Petalion Therapeutics to develop novel dendrimer-based treatments (ASX Announcement)

Apr 8th, 2024

Medicxi to invest up to USD $25M into newly established entity, Petalion Therapeutics, led by highly experienced pharmaceutical executive Dr Mehdi Shahidi

Half Yearly Report and Accounts (ASX Announcement)

Feb 28th, 2024

Starpharma (ASX: SPL, OTCQX: SPHRY) today releases its Interim Report and Half-Year Financial Results for the period ended 31 December 2023 (H1 FY24).

In the media

Which ASX companies are resurrecting abandoned drugs? Part 3

Apr 18th, 2024

"SPL has developed its proprietary Dendrimer Enhanced Products platform (DEP) to improve the effectiveness and safety of drugs, especially cancer treatments." Read the full article in Stockhead.

Which ASX companies are resurrecting abandoned drugs? Part 3

Apr 18th, 2024

DEP is based on dendrimers, which are highly branched polymers, to enhance the delivery of cancer treatments and reduce toxic side effects such as neutropenia, nausea, severe diarrhoea and hair loss from chemotherapy agents. Read the full article in The Australian Business Review.

Breaking new ground via an oncology treatment tech venture

Apr 9th, 2024

Cheryl Maley, CEO of Starpharma (SPL), provides insight into the partnreship with Medicxi, materialising in Petalion Therapeutics in the UK.